Article Text

Download PDFPDF
Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis–ulcerative colitis
  1. Li-Zsa Tan1,
  2. Claire R Reilly1,
  3. Lana C Steward-Harrison1,
  4. Fariha Balouch1,
  5. Richard Muir2,
  6. Peter J Lewindon1,3
  1. 1 Department of Gastroenterology, Lady Cilento Children’s Hospital, South Brisbane, Queensland, Australia
  2. 2 Department of Gastroenterology, The Wesley Hospital, Brisbane, Queensland, Australia
  3. 3 Queensland Children’s Medical Research Institute, University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to Professor Peter J Lewindon, Department of Gastroenterology, Lady Cilento Children’s Hospital, South Brisbane, QLD 4101, Australia; p.lewindon{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The report by Kummen et al 1 describing differences in gut microbial profile in patients with primary sclerosing cholangitis (PSC) and primary sclerosing cholangitis–ulcerative colitis (PSC–UC) compared with healthy controls and patients with UC without liver disease supports the tantalising prospect of microbiome manipulation as therapy for these conditions. The role of antibiotics in this setting, particularly in UC, is of great current interest2; The use of oral vancomycin (OV) for treatment of PSC was first reported by Cox and Cox3 in 1998, the focus then was treatment of liver disease, although it remains unclear if OV affects liver outcomes in PSC. We did, however, become interested in the description of improved clinical and endoscopic colitis in children with UC associated with PSC.Although typically mild, the colitis of PSC–UC or autoimmune sclerosing cholangitis–ulcerative colitis (ASC–UC) can be severe …

View Full Text


  • Contributors PJL formulated the study; L-ZT drafted and edited the manuscript; CRR, LCS-H, FB and RM contributed to study performance and data acquisition; PJL critically reviewed and approved the final manuscript.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval Children’s Health Queensland Human Ethics Research Committee (EC00175).

  • Provenance and peer review Not commissioned; externally peer reviewed.